Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Radiotherapy vs. Apatinib in HCC with PVTT
NCT03520257Phase 2Unknown
- Sponsor
- Guangxi Medical University
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03520257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520257.